MA54318B1 - Formulations de capsules - Google Patents
Formulations de capsulesInfo
- Publication number
- MA54318B1 MA54318B1 MA54318A MA54318A MA54318B1 MA 54318 B1 MA54318 B1 MA 54318B1 MA 54318 A MA54318 A MA 54318A MA 54318 A MA54318 A MA 54318A MA 54318 B1 MA54318 B1 MA 54318B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- solid solution
- methods
- capsule formulations
- capsules
- Prior art date
Links
- 239000007963 capsule composition Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 abstract 3
- 239000006104 solid solution Substances 0.000 abstract 3
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des formulations de capsules en solution solide du composé 1 et leurs procédés de préparation. L'invention concerne également des méthodes de traitement d'individus souffrant d'une maladie ou d'un trouble impliquant l'activation pathologique de récepteurs c5a, ou prédisposés à celui-ci, par l'administration d'une quantité efficace d'une ou plusieurs capsules en solution solide comprenant le composé 1. L'invention concerne en outre des capsules posologiques unitaires comprenant certaines quantités du composé 1, et des kits comprenant une capsule en solution solide comprenant le composé 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063547 WO2020112961A1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54318A MA54318A (fr) | 2021-10-06 |
| MA54318B1 true MA54318B1 (fr) | 2023-08-31 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54318A MA54318B1 (fr) | 2018-11-30 | 2019-11-27 | Formulations de capsules |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20200170957A1 (fr) |
| EP (2) | EP3886820B8 (fr) |
| JP (1) | JP7342124B2 (fr) |
| KR (1) | KR102586747B1 (fr) |
| CN (1) | CN113164403A (fr) |
| AR (1) | AR117219A1 (fr) |
| AU (1) | AU2019389031B2 (fr) |
| BR (1) | BR112021010285A2 (fr) |
| CA (1) | CA3120999A1 (fr) |
| CL (1) | CL2021001389A1 (fr) |
| CY (1) | CY1126079T1 (fr) |
| DK (1) | DK3886820T3 (fr) |
| ES (1) | ES2943492T3 (fr) |
| FI (1) | FI3886820T3 (fr) |
| HR (1) | HRP20230551T1 (fr) |
| HU (1) | HUE062551T2 (fr) |
| IL (1) | IL283450B2 (fr) |
| LT (1) | LT3886820T (fr) |
| MA (1) | MA54318B1 (fr) |
| MD (1) | MD3886820T2 (fr) |
| MX (1) | MX2021006242A (fr) |
| PL (1) | PL3886820T3 (fr) |
| PT (1) | PT3886820T (fr) |
| RS (1) | RS64250B1 (fr) |
| SG (1) | SG11202105572UA (fr) |
| SI (1) | SI3886820T1 (fr) |
| TW (1) | TWI827745B (fr) |
| WO (1) | WO2020112961A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020112961A1 (fr) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Formulations de capsules |
| US11844790B2 (en) * | 2020-10-28 | 2023-12-19 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| WO2023225533A1 (fr) * | 2022-05-19 | 2023-11-23 | Dow Global Technologies Llc | Utilisation de complexes interpolymères à base de peg pour une solubilisation améliorée de médicaments de classe ii bcs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| EP1817012A2 (fr) * | 2004-11-24 | 2007-08-15 | Merck & Co., Inc. | Formulations pharmaceutiques liquides et semi-solides pour administration par voie orale d'un amide substitue |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| CA2965223C (fr) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | Antagonistes de c5ar |
| JP5717768B2 (ja) * | 2010-03-10 | 2015-05-13 | アッヴィ・バハマズ・リミテッド | 固体組成物 |
| JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| CA2940984A1 (fr) | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Compositions pharmaceutiques solides d'antagonistes du recepteur des androgenes |
| EP3682879B1 (fr) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Procédés et intermédiaires pour la préparation d'antagonistes c5ar |
| WO2017123716A1 (fr) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Procédé de traitement d'une glomérulopathie à c3 |
| RU2748260C2 (ru) | 2016-04-04 | 2021-05-21 | Кемосентрикс, Инк. | РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ |
| EP4272821A3 (fr) | 2017-04-03 | 2024-01-03 | InflaRx GmbH | Traitement de maladies inflammatoires au moyen d'inhibiteurs de l'activité c5a |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3703687A4 (fr) | 2017-10-30 | 2021-04-07 | ChemoCentryx, Inc. | Composés deutérés utilisés comme immunomodulateurs |
| JP2021501159A (ja) | 2017-10-31 | 2021-01-14 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 |
| MA52808A (fr) | 2018-06-07 | 2021-04-14 | Chemocentryx Inc | Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca |
| WO2020112961A1 (fr) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Formulations de capsules |
-
2019
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/fr active Application Filing
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/fr active Active
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/fr active Active
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 CA CA3120999A patent/CA3120999A1/fr active Pending
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active IP Right Grant
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54318B1 (fr) | Formulations de capsules | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA37958A1 (fr) | Pde9i ayant un squelette imidazo pyrazinone | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA30607B1 (fr) | N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation | |
| EA202090573A1 (ru) | Составы нирапариба | |
| MA44037B1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
| MA33923B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA35875B1 (fr) | Dérivés d'aza-adamantane et leurs utilisations | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA53521B1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications | |
| MA34327B1 (fr) | Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes | |
| MA35882B1 (fr) | Inhibiteurs de pde9 comprenant un squelette imidazotriazinone | |
| MA29372B1 (fr) | Nouveaux composes derives du 5-thioxylose et leur utilisation therapeutique | |
| MA31933B1 (fr) | 5-[1'-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h-cyclopropa[a]naphtalen-4-yl) -3'-methylbutyl]-2,4,6-trihydroxy-1,3- benzenedicarboxaldehyde en tant que medicaments | |
| MA53977B1 (fr) | Compositions stables du sémaglutide et leurs utilisations | |
| FR3122085B1 (fr) | Compositions pharmaceutique et nutraceutique pour la prevention et le traitement de maladies neurodegeneratives | |
| MA34736B1 (fr) | Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
| MA49994B1 (fr) | Composés macrocycliques pour le traitement de maladie |